Cargando…

Retinoblastoma in a 23-year-old adult treated with primary intra-arterial and intravitreal chemotherapy

Intra-arterial chemotherapy (IAC) continues to provide a globe-sparing alternative as primary treatment for retinoblastoma with few adverse events. While there is growing evidence to highlight the utility of IAC in children with retinoblastoma, adult cases treated with primary IAC have not previousl...

Descripción completa

Detalles Bibliográficos
Autores principales: McMahon, Jeffrey F., Jabbour, Pascal, Shields, Carol L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561044/
https://www.ncbi.nlm.nih.gov/pubmed/31198299
http://dx.doi.org/10.4103/ojo.OJO_162_2018
_version_ 1783426078628380672
author McMahon, Jeffrey F.
Jabbour, Pascal
Shields, Carol L.
author_facet McMahon, Jeffrey F.
Jabbour, Pascal
Shields, Carol L.
author_sort McMahon, Jeffrey F.
collection PubMed
description Intra-arterial chemotherapy (IAC) continues to provide a globe-sparing alternative as primary treatment for retinoblastoma with few adverse events. While there is growing evidence to highlight the utility of IAC in children with retinoblastoma, adult cases treated with primary IAC have not previously been characterized. We describe a rare case of Group D retinoblastoma in a 23-year-old adult treated successfully with IAC and intravitreal chemotherapy. This is a retrospective case report of a single patient. Subsequent to IAC and intravitreal chemotherapeutic treatments, at last follow-up 14 months following initial presentation and 8 months since last treatment, the retinoblastoma demonstrated complete regression into a partially calcified scar, with complete resolution of intravitreal and subretinal seeds and no evidence of tumor recurrence. Visual acuity improved to 20/30 in the left eye. There were no adverse events from therapy. Despite its rarity, it is important to consider retinoblastoma in the differential diagnosis of a white mass, even in an adult. Furthermore, this case highlights the utility of IAC for retinoblastoma, despite older patient age.
format Online
Article
Text
id pubmed-6561044
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-65610442019-06-13 Retinoblastoma in a 23-year-old adult treated with primary intra-arterial and intravitreal chemotherapy McMahon, Jeffrey F. Jabbour, Pascal Shields, Carol L. Oman J Ophthalmol Case Report Intra-arterial chemotherapy (IAC) continues to provide a globe-sparing alternative as primary treatment for retinoblastoma with few adverse events. While there is growing evidence to highlight the utility of IAC in children with retinoblastoma, adult cases treated with primary IAC have not previously been characterized. We describe a rare case of Group D retinoblastoma in a 23-year-old adult treated successfully with IAC and intravitreal chemotherapy. This is a retrospective case report of a single patient. Subsequent to IAC and intravitreal chemotherapeutic treatments, at last follow-up 14 months following initial presentation and 8 months since last treatment, the retinoblastoma demonstrated complete regression into a partially calcified scar, with complete resolution of intravitreal and subretinal seeds and no evidence of tumor recurrence. Visual acuity improved to 20/30 in the left eye. There were no adverse events from therapy. Despite its rarity, it is important to consider retinoblastoma in the differential diagnosis of a white mass, even in an adult. Furthermore, this case highlights the utility of IAC for retinoblastoma, despite older patient age. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6561044/ /pubmed/31198299 http://dx.doi.org/10.4103/ojo.OJO_162_2018 Text en Copyright: © 2019 Oman Ophthalmic Society http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Case Report
McMahon, Jeffrey F.
Jabbour, Pascal
Shields, Carol L.
Retinoblastoma in a 23-year-old adult treated with primary intra-arterial and intravitreal chemotherapy
title Retinoblastoma in a 23-year-old adult treated with primary intra-arterial and intravitreal chemotherapy
title_full Retinoblastoma in a 23-year-old adult treated with primary intra-arterial and intravitreal chemotherapy
title_fullStr Retinoblastoma in a 23-year-old adult treated with primary intra-arterial and intravitreal chemotherapy
title_full_unstemmed Retinoblastoma in a 23-year-old adult treated with primary intra-arterial and intravitreal chemotherapy
title_short Retinoblastoma in a 23-year-old adult treated with primary intra-arterial and intravitreal chemotherapy
title_sort retinoblastoma in a 23-year-old adult treated with primary intra-arterial and intravitreal chemotherapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561044/
https://www.ncbi.nlm.nih.gov/pubmed/31198299
http://dx.doi.org/10.4103/ojo.OJO_162_2018
work_keys_str_mv AT mcmahonjeffreyf retinoblastomaina23yearoldadulttreatedwithprimaryintraarterialandintravitrealchemotherapy
AT jabbourpascal retinoblastomaina23yearoldadulttreatedwithprimaryintraarterialandintravitrealchemotherapy
AT shieldscaroll retinoblastomaina23yearoldadulttreatedwithprimaryintraarterialandintravitrealchemotherapy